Company news
Pulmatrix, Inc. (NASDAQ:PULM) news
Pulmatrix, Inc. news releases on 6ix. Latest, Aug 13, 2026: Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Press releases & updates
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
August 13, 2026
Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
April 21, 2026
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
April 13, 2026
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
March 25, 2026
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
March 1, 2026
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
February 26, 2026
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
December 18, 2025
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
October 16, 2025
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
August 6, 2025
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
May 15, 2025
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
March 21, 2025
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain
January 21, 2025
Pulmatrix and Cullgen Announce Proposed Merger
November 12, 2024
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 7, 2024
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
May 28, 2024
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine
May 16, 2024
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
May 14, 2024
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
March 27, 2024
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
January 7, 2024
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 8, 2023
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
September 18, 2023
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
August 22, 2023
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
July 10, 2023
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
June 14, 2023
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
May 23, 2023
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
Pulmatrix Supports World Asthma Day 2023
May 1, 2023
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
March 29, 2023
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
February 5, 2023
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
January 24, 2023
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
January 22, 2023
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
January 3, 2023
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 9, 2022
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
September 25, 2022
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 7, 2022
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
July 11, 2022
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
March 28, 2022
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
March 20, 2022
Pulmatrix Regains Compliance With Nasdaq Listing Requirements
March 16, 2022
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
February 28, 2022
Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split
February 23, 2022
Pulmatrix Issues Letter to Stockholders
January 31, 2022
Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering
December 16, 2021
Pulmatrix Announces $6.75 Million Registered Direct Offering
December 14, 2021
Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update
November 9, 2021